Dataset: Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer

Background: The JBR.10 trial demonstrated significant survival benefit from adjuvant cisplatin/vinorelbine (ACT) in stage IB-II NSCLC (HR...

Registered by ArrayExpress Uploader

View Dataset

Background: The JBR.10 trial demonstrated significant survival benefit from adjuvant cisplatin/vinorelbine (ACT) in stage IB-II NSCLC (HR 0.69, p=0.04), but stage IB patients did not derive significant benefit (HR: 0.94, p= 0.79). We hypothesized that expression profiling could identify stage-independent subgroups of patients who might benefit from adjuvant chemotherapy. Methods: Gene expression profiling was conducted on mRNA isolated from frozen JBR.10 tumor samples (either from patients under observation [OBS], or treated with ACT). The minimum gene set that selected for the greatest separation of good and poor prognosis patient subgroups in OBS patients was identified and this gene signature was used to classify patients into high and low risk for death after surgery, and predict ACT effect. The prognostic gene signature was additionally tested on ACT patients and publicly available microarray datasets. Results: A 15-gene signature separated OBS patients into equal high and low risk subgroups with significantly different prognoses (HR 15.02, 95% CI 5.12-44.04, p=0.0001). The signature was prognostic in both stage IB and II. It was also predictive of improved survival following ACT treatment in high-risk patients (HR 0.33, 95% CI 0.17-0.63, p=0.0005), but not in low risk patients (HR 3.67, 95% CI 1.22-11.06, p=0.0133; interaction p=0.0001). The prognostic effect of the signature was validated in two independent gene expression datasets of 169 stage I-II adenocarcinoma and 106 squamous cell carcinoma patients. Conclusions: This microarray-based 15-gene prognostic expression signature is stage and histology independent and may select early stage NSCLC patients who are most likely to benefit from adjuvant chemotherapy with cisplatin/vinorelbine. Keywords: Expression profiling by microarray; prognosis prediction 90 samples

Species:: human
Samples:: 90
Source:: E-GEOD-14814
PubMed:: 20823422
Updated:: Dec.12, 2014
Registered:: Jun.19, 2014

Factors: (via ArrayExpress)

Sample	CAUSE OF DEATH	POST SURGICAL TREATMENT	OS STATUS	OS TIME	SEX	HISTOLOGY TYPE	DSS TIME	DSS STATUS	AGE	STAGE
GSM371002	Other conditions	ACT	Dead	6.03	male	ADC	6.03	Alive	56.8
GSM37100	Lung cancer	OBS	Dead	2.04	female	ADC	2.04	dead	57.4	II
GSM371000	Alive	OBS	Alive	5.38	male	ADC	5.38	Alive	63.2
GSM370999	Alive	ACT	Alive	6.74	female	ADC	6.74	Alive	41
GSM370998	Alive	OBS	Alive	5.68	female	SQCC	5.68	Alive	57	II
GSM370997	Lung cancer	ACT	Dead	4.76	female	ADC	4.76	dead	62	II
GSM370996	Lung cancer	ACT	Dead	6.66	male	SQCC	6.66	dead	66.9	II
GSM370995	Lung cancer	ACT	Dead	1.70	male	SQCC	1.70	dead	75.3	II
GSM370994	Lung cancer	OBS	Dead	1.14	male	SQCC	1.14	dead	66.5
GSM370993	Lung cancer	OBS	Dead	1.10	male	SQCC	1.10	dead	55.8	II
GSM370992	Alive	ACT	Alive	4.89	female	ADC	4.89	Alive	58.4	II
GSM37099	Alive	ACT	Alive	8.18	male	SQCC	8.18	Alive	57.4
GSM370990	Alive	ACT	Alive	7.77	male	SQCC	7.77	Alive	70.4
GSM370989	Alive	OBS	Alive	2.86	male	SQCC	2.86	Alive	65.3	II
GSM370988	Other conditions	ACT	Dead	5.67	male	SQCC	5.67	Alive	72.4
GSM370987	Alive	ACT	Alive	3.51	female	ADC	3.51	Alive	66.3
GSM370986	Alive	ACT	Alive	3.95	female	ADC	3.95	Alive	69.7	II
GSM370985	Alive	OBS	Alive	4.46	male	ADC	4.46	Alive	67.4
GSM370984	Lung cancer	OBS	Dead	1.50	male	ADC	1.50	dead	69.2	II
GSM370983	Alive	ACT	Alive	9.22	male	SQCC	9.22	Alive	62.1	II
GSM370982	Lung cancer	OBS	Dead	5.00	male	SQCC	5.00	dead	59	II
GSM37098	Lung cancer	OBS	Dead	2.43	male	SQCC	2.43	dead	55.6	II
GSM370980	Alive	ACT	Alive	9.01	male	LCUC	9.01	Alive	61.6
GSM370979	Lung cancer	OBS	Dead	2.82	male	ADC	2.82	dead	65.8	II
GSM370978	Alive	ACT	Alive	4.74	female	SQCC	4.74	Alive	69.4
GSM370977	Lung cancer	OBS	Dead	2.18	female	LCUC	2.18	dead	60.4
GSM370976	Lung cancer	OBS	Dead	1.86	female	ADC	1.86	dead	45.8
GSM370975	Alive	ACT	Alive	4.09	male	SQCC	4.09	Alive	51.2
GSM370974	Other conditions	OBS	Dead	1.96	male	SQCC	1.96	Alive	58.5	II
GSM370973	Alive	ACT	Alive	6.54	male	SQCC	6.54	Alive	45.4	II
GSM370972	Lung cancer	ACT	Dead	0.63	male	LCUC	0.63	dead	50.5
GSM37097	Alive	ACT	Alive	6.87	male	SQCC	6.87	Alive	59.1	II
GSM370970	Alive	OBS	Alive	6.86	female	SQCC	6.86	Alive	58.1	II
GSM370969	Lung cancer	OBS	Dead	0.78	male	SQCC	0.78	dead	67.9
GSM370968	Alive	ACT	Alive	7.04	male	SQCC	7.04	Alive	60.5	II
GSM370967	Lung cancer	ACT	Dead	0.43	female	LCUC	0.43	dead	59.5	II
GSM370966	Alive	ACT	Alive	5.31	male	SQCC	5.31	Alive	70.3
GSM370965	Alive	OBS	Alive	5.88	male	SQCC	5.88	Alive	64.3
GSM370964	Other conditions	OBS	Dead	3.17	male	SQCC	3.17	Alive	69
GSM370963	Alive	OBS	Alive	7.12	male	SQCC	7.12	Alive	54.8
GSM370962	Lung cancer	OBS	Dead	2.28	male	ADC	2.28	dead	63.5	II
GSM37096	Alive	ACT	Alive	6.24	male	SQCC	6.24	Alive	64.1	II
GSM370960	Alive	OBS	Alive	6.09	male	SQCC	6.09	Alive	74.4	II
GSM370959	Alive	ACT	Alive	5.12	male	SQCC	5.12	Alive	73.1
GSM370958	Alive	ACT	Alive	5.03	female	ADC	5.03	Alive	56.5	II
GSM370957	Alive	OBS	Alive	6.44	male	SQCC	6.44	Alive	62.8
GSM370956	Alive	ACT	Alive	5.42	male	ADC	5.42	Alive	63.7
GSM370955	Lung cancer	OBS	Dead	1.18	male	LCUC	1.18	dead	66.5	II
GSM370954	Lung cancer	ACT	Dead	1.88	male	SQCC	1.88	dead	65.7
GSM370953	Alive	ACT	Alive	7.88	male	SQCC	7.88	Alive	75.8
GSM370952	Alive	OBS	Alive	7.94	male	SQCC	7.94	Alive	69.6
GSM37095	Alive	OBS	Alive	5.87	female	ADC	5.87	Alive	38.2
GSM370950	Lung cancer	OBS	Dead	0.74	male	LCUC	0.74	dead	42.7	II
GSM370949	Lung cancer	ACT	Dead	1.64	male	SQCC	1.64	dead	66.2	II
GSM370948	Alive	OBS	Alive	6.76	male	SQCC	6.76	Alive	63.3	II
GSM370947	Alive	ACT	Alive	6.71	male	SQCC	6.71	Alive	48.8	II
GSM370946	Lung cancer	OBS	Dead	2.29	male	SQCC	2.29	dead	56.4
GSM370945	Alive	ACT	Alive	6.73	male	SQCC	6.73	Alive	61.6
GSM370944	Alive	ACT	Alive	7.20	male	ADC	7.20	Alive	58.2	II
GSM370943	Alive	ACT	Alive	7.43	male	SQCC	7.43	Alive	61.3	II
GSM370942	Alive	ACT	Alive	7.21	male	SQCC	7.21	Alive	72.9
GSM37094	Lung cancer	ACT	Dead	3.74	male	ADC	3.74	dead	62.7	II
GSM370940	Alive	OBS	Alive	7.94	male	SQCC	7.94	Alive	62.1	II
GSM370939	Lung cancer	ACT	Dead	0.90	female	ADC	0.90	dead	75.6
GSM370938	Lung cancer	ACT	Dead	1.20	male	LCUC	1.20	dead	81.3
GSM370937	Lung cancer	ACT	Dead	1.09	male	SQCC	1.09	dead	65.4
GSM370936	Alive	ACT	Alive	7.24	female	SQCC	7.24	Alive	53
GSM370935	Alive	ACT	Alive	7.71	male	ADC	7.71	Alive	68.8	II
GSM370934	Alive	OBS	Alive	6.93	female	ADC	6.93	Alive	50.2
GSM370933	Other conditions	ACT	Dead	0.19	male	ADC	0.19	Alive	63.2	II
GSM370932	Alive	OBS	Alive	8.02	female	SQCC	8.02	Alive	63.4	II
GSM37093	Other conditions	ACT	Dead	6.09	male	ADC	6.09	Alive	59.4
GSM370930	Alive	ACT	Alive	7.53	female	SQCC	7.53	Alive	48.2	II
GSM370929	Alive	OBS	Alive	3.00	male	SQCC	3.00	Alive	72.5
GSM370928	Lung cancer	OBS	Dead	1.59	female	ADC	1.59	dead	63.5
GSM370927	Alive	ACT	Alive	8.48	male	SQCC	8.48	Alive	66.6
GSM370926	Other conditions	OBS	Dead	6.17	male	SQCC	6.17	Alive	73
GSM370925	Alive	ACT	Alive	9.29	male	SQCC	9.29	Alive	73.3	II
GSM370924	Alive	OBS	Alive	8.55	male	LCUC	8.55	Alive	60.8
GSM370923	Alive	ACT	Alive	8.71	male	LCUC	8.71	Alive	48.3
GSM370922	Other conditions	OBS	Dead	1.66	male	SQCC	1.66	Alive	70.6	II
GSM37092	Alive	ACT	Alive	8.60	male	ADC	8.60	Alive	65.5	II
GSM370920	Other conditions	ACT	Dead	0.03	female	ADC	0.03	Alive	67.2
GSM370919	Lung cancer	OBS	Dead	0.69	male	SQCC	0.69	dead	64.8	II
GSM370918	Lung cancer	OBS	Dead	2.06	male	SQCC	2.06	dead	69.2	II
GSM370917	Alive	ACT	Alive	8.23	female	ADC	8.23	Alive	65.7
GSM370916	Alive	ACT	Alive	8.66	male	LCUC	8.66	Alive	57.1	II
GSM370915	Lung cancer	ACT	Dead	1.32	male	SQCC	1.32	dead	64.1	II
GSM370914	Alive	OBS	Alive	9.03	male	SQCC	9.03	Alive	53.4
GSM370913	Alive	OBS	Alive	8.52	female	ADC	8.52	Alive	44.9	II